Background and objective: Mannitol challenge testing is an established tool for clinical asthma diagnosis, and can be performed outside of specialized respiratory laboratories. Despite applicability in both clinical and non-clinical populations, with different pre-test asthma probabilities, differences in diagnostic properties have not been well explored. This study aimed to quantify the diagnostic utility of mannitol challenge testing for asthma in a community cohort and a symptomatic wheezing subset of this cohort. Methods: During the 22-year follow-up of the Western Australian Pregnancy (Raine) Cohort, 772 participants (384 males) completed mannitol challenge and skin prick testing and respiratory health questionnaires, of whom 148 reporting wheeze in the past 12 months were included in a wheezing subset. Results: Responsiveness to mannitol had low sensitivity (19%) and high specificity (97%) to identify current asthma in the complete cohort, with positive and negative predictive values (PPV and NPV) of 45% and 92%, respectively. Within the wheezing subset, sensitivity (19%) and specificity (94%) remained similar, but PPV increased to 79%, and NPV decreased to 52%. Conclusion: Our findings support previously reported high specificity and good PPV for mannitol challenge testing in symptomatic wheezing populations, and highlight the need for caution when interpreting mannitol test results in non-clinical populations.
INTRODUCTION
Bronchial hyper-responsiveness (BHR) is associated with asthma and airway inflammation. 1 Inhaled bronchial challenge tests to identify BHR are especially useful for diagnostic investigation of patients with symptoms suggestive of asthma, who show normal pulmonary function and no bronchodilator reversibility. Bronchial challenge tests are classified as direct or indirect depending on mode of action. Direct bronchial challenge tests involve inhaling agents such as histamine or methacholine that act directly upon airway smooth muscles to induce bronchoconstriction 1 ; they are considered to have high diagnostic sensitivity for asthma and are primarily used to exclude diagnosis of asthma (i.e. high negative predictive value (NPV)). 2 Indirect bronchial challenge tests provoke bronchoconstriction via activation of inflammatory pathways, with inhaled agents such as mannitol and hypertonic saline, or physical stimulation such as exercise or eucapnic hyperventilation. 1, 3 Studies to date suggest that a positive indirect challenge test is closely associated with airway inflammation, and clinically they are regarded 
SUMMARY AT A GLANCE
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as having high specificity for asthma diagnosis and high positive predictive value (PPV). 4 The mannitol challenge test is an indirect bronchial challenge test 3 that is easy to administer, inexpensive and has one standardized protocol for use; as no nebulizer is required, it facilitates point of care testing, offering the potential for use outside of specialized respiratory laboratories. 5 The reported sensitivity and specificity of the mannitol challenge test to identify asthma is inconsistent. Studies in clinical populations of patients with diagnosed asthma have reported high PPV and specificity, with moderate sensitivity. 3, 6 In contrast, two studies in non-clinical cohorts reported high NPV (>85%) and variable PPV (55% and 91%). [7] [8] [9] These studies assessing mannitol challenge testing for asthma in a community cohort and in military conscripts present uniformly high NPV that would not traditionally be expected from indirect bronchial challenge testing. [7] [8] [9] The ease of implementing mannitol testing outside of the respiratory clinic suggests that, in addition to the current applications mentioned above, 'mannitol is likely to become increasingly used in children and young adults participating in sports who do not have other symptoms of asthma'. 5 It is therefore important that potential variation in the diagnostic accuracy of mannitol testing, when applied to non-clinical populations, is elucidated to ensure appropriate interpretation of an individual's results.
The current study investigated how the diagnostic utility of mannitol challenge testing for asthma varies between two population groups: a 'general population' of young adults from a large community cohort and a 'clinical wheezing population' subset with wheezing symptoms, representing those most likely to be referred clinically for bronchial challenge testing.
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METHODS
Study design
This cross-sectional population study was conducted within the 22-year follow-up of the Western Australian Pregnancy Cohort (Raine) Study. 11 The Raine Study cohort has been detailed previously. 12, 13 At the 22-year follow-up, there were 2086 participants still involved in the cohort. This study was approved by the University of Western Australian human research ethics approval committee (RA/4/1/5202).
Participants attending the 22-year follow-up completed a respiratory health questionnaire, skin prick testing, spirometry and a mannitol challenge test. All participants were requested to withhold antihistamines and asthma medications for 72 h prior to testing, and were questioned to verify medication withholding on the day of testing.
Spirometry and mannitol challenge test
Mannitol challenge testing was performed according to the manufacturer's recommendations (Pharmaxis Ltd, Frenchs Forest, Australia). Baseline spirometry and forced expiratory volume in 1 s (FEV 1 ) measurements during challenge testing were performed according to European Respiratory Society/American Thoracic Society (ERS/ATS) spirometry guidelines using an nSpire Health KOKO PFT spirometer (nSpire Health, Inc., Longmont, Colorado, USA).
14 Challenge testing was stopped if a 15% drop in FEV 1 from testing baseline or a 10% drop between doses occurred (indicating a positive test), or when the maximum cumulative dose of 635 mg had been administered. Baseline spirometry data are reported in absolute and predicted terms. Predicted lung function was based on the 2012 Global Lung Function Initiative equations, 15 the validity of which has been confirmed in an Australasian population. 16 
Skin prick testing
Skin prick testing was performed according to Australasian guidelines. 17 Allergens used were: dust mites Dermatophagoides farinae and Dermatophagoides pteronyssinus, perennial rye grass, grass mix, histamine hydrochloride 10 mg/mL positive control and glycerine/saline negative control. A positive result indicating sensitization was recorded for each allergen wheal with an average diameter measurement exceeding the negative control by >3 mm. All participants who did not display a positive control wheal diameter ≥4 mm were excluded from the analysis.
17
Asthma definitions
The general population included all participants completing questionnaires, spirometry, skin prick and mannitol challenge testing. The clinical wheezing population included participants from the general population who answered positively in their questionnaire to wheezing in the past 12 months, representing those with symptoms suggestive of asthma, most likely to be referred clinically for bronchial challenge testing.
We defined 'current asthma' as previously reported in Raine cohort studies [18] [19] [20] ; participants who reported ever having doctor-diagnosed asthma AND wheezing in the past 12 months AND using asthma medication(s) in the past 12 months. 'No current asthma' was defined as all participants not meeting the definition for current asthma.
Statistical analysis
Data were analysed with SPSS version 22.0 (SPSS, Inc., Chicago, IL, USA). Data are reported as means (SD) for normally distributed variables. Independent sample t-tests were used to compare means and chi-square tests were used to compare proportions against the current asthma group and exact Clopper-Pearson 95% CIs for proportions were estimated. Sensitivity was calculated as the proportion of positive mannitol tests in the current asthma group, and specificity as the proportion of negative mannitol tests in the no current asthma group. Similarly, PPV was calculated as the proportion with current asthma in the positive mannitol group and NPV as the proportion without current asthma in the negative mannitol group.
RESULTS
The 22-year Raine Study follow-up included 1234 participants. Successful data collection was obtained from spirometry and mannitol challenge testing in 963 and 899 individuals, respectively. General, medical and respiratory questionnaires were completed by 1130 participants, and 846 produced valid results from skin prick testing. The final dataset included 772 participants with complete questionnaire, spirometry, mannitol challenge and skin prick testing data. Characteristics of the study population are shown in Table 1 . Thirty-three (4%) participants had a positive mannitol challenge test. Mannitol testing was contraindicated in three participants due to FEV 1 < 60% predicted; these participants were excluded from the dataset and subsequent analysis.
There were no significant differences in assessed variables between the 1130 participants completing questionnaires at the 22-year follow-up, and those 772 included in the final analysis (Table S1 , Supplementary Information).
Within the general population, 10% of participants met the definition for current asthma. Those with current asthma were significantly more likely to return a positive mannitol challenge test and had significantly higher prevalence for sensitization to dust mite or grass pollen than the no current asthma group (Table 1) . Both mean FEV 1 /forced vital capacity (FVC) and mean FEV 1 percent predicted were significantly lower in the current asthma group, but there were no significant differences in age, sex or current smoking between the groups by asthmatic status. However, as expected, significantly more current asthmatic patients used inhaled corticosteroids (ICSs) and beta-2 agonists in the past year (Table 1) .
Within the subset of clinical wheezing participants, 52% satisfied the criteria for current asthma and they were significantly more likely to have a positive mannitol challenge test and to have used ICS in the past 12 months compared with no current asthma participants (Table 1 ). There were no differences in age, sex, positive skin prick results, current smoking or FEV 1 and FEV 1 /FVC measurements between current asthma and no current asthma groups (Table 1) .
Diagnostic utility of mannitol challenge testing
Within the general population, 15 (19%) participants with current asthma had a positive mannitol challenge test, indicating 19% sensitivity, and 18 (3%) participants with no current asthma had a positive mannitol challenge test corresponding to 97% specificity ( Table 2 ). The PPV was 45%, while the NPV was 92% ( Table 2) .
We also assessed diagnostic utility after excluding 20 participants who used ICS in the past 12 months and did not respond positively to mannitol. The proportion of current asthmatic patients responding positively to mannitol was 23%, but there was no real change in sensitivity, specificity, PPV or NPV (Table 2) . Participant characteristics compared between current asthma and no current asthma groups for general population and a subset of clinical wheezing population using independent sample t-tests to compare means and chi-square analysis to compare proportions, with P < 0.05 indicating a significant difference.
CI, confidence interval; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroid; SD, standard deviation.
The diagnostic utility of mannitol challenge testing for asthma was also assessed within the clinical wheezing population, resulting in similar sensitivity and specificity to the general population, but with increased PPV and decreased NPV ( Table 2) . Excluding participants with a negative mannitol test using ICS resulted in no real change (Table 2) .
DISCUSSION
Mannitol challenge testing is extending beyond traditional use within clinical respiratory laboratories and clinical populations, and is now recommended for non-clinical populations such as athletes, military recruits and firefighters, and is increasingly used in asymptomatic children and young adults participating in sports. 5, 10, 21, 22 This study sought to determine the diagnostic utility of mannitol challenge testing within these two potential referral sources: a clinical wheezing population experiencing wheezing in the past year and a community-based general population. In the context of the general population, mannitol challenge testing had low sensitivity and high specificity in keeping with other studies of non-clinical cohorts; and in agreement with data published by Miedinger et al. we observed a lower PPV than seen in clinical trials. 7, 9 Within our clinical wheezing population, we found similar sensitivity and specificity to that observed in our general population, although PPV increased to 79% and NPV decreased to 52%, which echoed the results of Anderson et al.'s study of participants with normal FEV 1 and mild asthma symptoms. 2 Although participants were required to withhold asthma medications 72 h prior to testing, this may not have been sufficient to wash-out ICS prior to bronchial challenge testing resulting in a negative mannitol test due to attenuation of BHR. 1 We therefore reassessed diagnostic utility after removing participants with a negative mannitol test who had used ICS in the past 12 months (n = 26). Excluding these participants did not change diagnostic utility (Table 2 ), suggesting they may not have recently used ICS or their airway inflammation may be sub-optimally controlled.
In keeping with previous follow-up of the Raine Study cohort, current asthma was defined according to participant's questionnaire answers; this is in contrast to other studies that used prospective physician diagnosis. 2, [6] [7] [8] 23 Our definition of current asthma may have excluded participants currently experiencing asthma symptoms who were under-medicated or not sensitive to their wheezing, and also asthmatic patients whose symptoms were well controlled by medication. Despite this, 10% of participants met our criteria for current asthma which is consistent with the documented asthma prevalence in Australia. 24 This suggests that our diagnostic method may be a reasonable approximation of physician-diagnosed asthma in the context of a community cohort.
The significant associations we found between sensitization to dust mite and grass pollen and asthma, wheezing and BHR (Table 1) have been well established in this and other cohort studies, so these results were as expected. 19, 25, 26 Our study was conducted exclusively in young adults with a mean (range) age of 22 (21) (22) (23) years. Although children as young as 4 years of age are capable of completing mannitol challenge testing, results from our study should not be extended to paediatric populations. 27 Populations of older adults often present with extensive smoking histories and more advanced disease, possibly with COPD features and airways remodelling, also limiting potential applicability in older populations. 28, 29 Cigarette smoking is associated with increased hyper-responsiveness to bronchial challenge agents, including mannitol; however, both general and clinical wheezing populations demonstrated no association with smoking and positive mannitol testing. 30, 31 As our participants were aged only 22 years, their smoking history was probably insufficient to result in chronic irritation and inflammation of bronchial mucosa and subsequently increased BHR. 30, 32 The overall prevalence of current smoking in our general population (16%) closely reflects the underlying Australian adult population (17%), suggesting that our results may be applicable in populations with community-level smoking prevalence, but may not be generalizable in higher smoking prevalence populations. 33 The Australian Bureau of Statistics reports in the 2011-2012 census that 38% of 18-24 year olds were overweight or obese with BMI ≥ 25. 34 Obesity rates were therefore as expected in the general population and because obesity is increasingly recognized as a risk factor in asthma development, higher obesity rates in the clinical wheezing population were also as expected 35 (Table 1 ). All participant groups in our study, including current asthma and clinical wheezing groups, had normal pulmonary function, with z-scores greater than −1.64 for FEV 1 and FEV 1 /FVC 14, 15 and only 4% of the general population and 17% of the clinical wheezing population reported using ICS in the past 12 months. This suggests that asthmatic patients in our study primarily had mild asthma, without obvious respiratory impairment, representative of the underlying community population and also the clinical population with an unclear asthma diagnosis most likely to be referred for bronchial challenge testing. As such, our results may not be applicable to populations of moderate to severe asthmatic patients or with impaired pulmonary function who would likely demonstrate higher pre-test probability for asthma and enhanced diagnostic utility.
Our definition of current asthma was based upon reported wheezing and asthma medication use in the past 12 months. Tightening this definition by more recent symptoms and medication use may have also boosted the pre-test probability of asthma and resulted in increased diagnostic power for the mannitol challenge test; however, this is unable to be assessed with the data available.
In this study, we found mannitol challenge testing to have high specificity (94%) and moderate to high PPV (79%) when applied to a symptomatic clinical wheezing population. These results were anticipated for an indirect bronchial challenge test and in keeping with results reported by Anderson et al. 2, 6 When applied to a general population, we still found high specificity (97%); however, PPV was low at 45% and NPV was high at 92%, similar to other studies in non-clinical cohorts. [7] [8] [9] Our findings support previous reports of high specificity and good PPV for mannitol challenge testing in symptomatic wheezing populations, but highlight the need for caution when interpreting results of mannitol challenge testing for asthma in non-clinical populations such as population cohorts, athletes, firefighters and military personal.
